Transcenta Holding Limited has announced that its partner, Inhibrx Biosciences, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with Fast Track and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.
